1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Chronic hepatitis C is a persistent infection of hepatocytes by the hepatitis C virus (HCV), a single-stranded RNA flavivirus transmitted predominantly through percutaneous blood exposure: unsafe injections, unscreened transfusion, injecting drug use, and, in Indonesia historically, nosocomial and dialysis-associated routes. Roughly three-quarters of acute infections become chronic because the virus evades durable immune clearance, driving decades of slowly progressive necroinflammation and hepatic fibrosis. About 15-30% of untreated patients develop cirrhosis, carrying a 1-4% annual risk of hepatocellular carcinoma (HCC) plus risk of decompensation, variceal bleeding, and liver failure; HCV is among the leading indications for liver transplantation worldwide and carries extrahepatic sequelae (WHO 2024; NICE TA363 2015). The virus replicates via the NS5B RNA-dependent RNA polymerase and the NS5A replication complex, the molecular targets of modern direct-acting antivirals. Because most infection is asymptomatic until advanced disease, HCV is a silent, late-presenting driver of cirrhosis and liver cancer; crucially, sustained virologic response now equates to virological cure, making chronic HCV one of the few curable chronic viral diseases.
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
Globally, WHO estimated 50 million people living with chronic HCV in 2022, with nearly 1 million new infections and approximately 242,000 HCV-attributable deaths that year; viral hepatitis collectively caused 1.3 million deaths, of which 17% were due to HCV. Only 36% of infections were diagnosed and 20% treated (WHO Global Hepatitis Report 2024). In Indonesia, the 2007 Riskesdas survey (n=11,762) found anti-HCV seroprevalence of about 0.8% (range 0.1% in Sumatera Barat to 1.7% in Aceh) and viraemic prevalence around 0.5%, corresponding to roughly 1.2 million viraemic individuals (Muljono 2017; Mardian et al. 2017; Wasitthankasem et al. 2016). Burnet/Bristol elimination modelling estimated approximately 1.9 million Indonesians chronically infected (Trickey et al. 2020). Prevalence concentrates on Java, in older adults (peak ages 50-54), and in key populations including people who inject drugs and people living with HIV. Genotype 1, predominantly subtype 1b (around 47%), is the most common genotype (Utama et al. 2010).
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
International guidelines (WHO, AASLD-IDSA, EASL) recommend short-course, all-oral DAA therapy achieving sustained virologic response (SVR, virologic cure) in over 95% of patients, and increasingly favour pan-genotypic regimens; pegylated interferon plus ribavirin is obsolete, having achieved SVR of only roughly 40-50% in genotype 1 with substantial toxicity (Manns 2011). Ledipasvir/sofosbuvir (Harvoni) was the pivotal genotype 1/4 single-tablet regimen, but global practice has shifted toward pan-genotypic combinations, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. In Indonesia, the de facto standard since the 2017 free-DAA programme has been generic sofosbuvir plus daclatasvir (12 weeks for non-cirrhotic, 24 weeks often with ribavirin for cirrhotic), with real-world SVR12 around 95-96% (Yunihastuti et al. 2021; Kemenkes PNPK 2019), increasingly supplemented by pangenotypic sofosbuvir/velpatasvir. Limitations are programmatic rather than pharmacological: constrained annual treatment quotas, low diagnosis and linkage-to-care rates, fragmented HCV-RNA confirmatory testing, and uneven specialist access outside Java.
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
The US FDA approved sofosbuvir/ledipasvir (Harvoni) on 10 October 2014 as the first once-daily single-tablet, interferon-free regimen for genotype 1 chronic HCV; the EMA granted marketing authorisation in November 2014 (Gilead 2014; EMA EPAR). NICE recommended ledipasvir/sofosbuvir for genotype 1 and 4 chronic HCV in technology appraisal TA363 (published 25 November 2015), with 8 weeks for treatment-naive non-cirrhotic genotype 1 and 12 weeks for treatment-experienced disease (NICE TA363 2015). In Indonesia, the fixed-dose ledipasvir/sofosbuvir product has had limited uptake; the national programme and PNPK Tata Laksana Hepatitis C (KMK HK.01.07/MENKES/681/2019) instead procure generic sofosbuvir and daclatasvir (registered and supplied, in part via Kimia Farma, from around 2017-2018) and pangenotypic sofosbuvir/velpatasvir, provided free for eligible patients with BPJS/JKN coverage. Sofosbuvir-based DAA therapy is included in the Formularium Nasional; the precise current Fornas line-listing for the ledipasvir/sofosbuvir co-formulation is not clearly documented in accessible sources and should be verified against the latest Kemenkes Fornas update (Kemenkes 2019).
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Ledipasvir dan sofosbuvir 90/400 mg sekali sehari selama 12 minggu | Rp 29,6 juta | 16,330 | 30,58 |
| tanpa antivirus kerja langsung (perjalanan alamiah penyakit) | Rp 89,4 juta | 12,648 | 25,07 |
| Selisih | -Rp 59,7 juta | 3,682 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (35 yr) | 3,682 | -Rp 59,7 juta | Lebih efektif dan lebih hemat |
| 5-year horizon | 0,398 | -Rp 3,5 juta | Lebih efektif dan lebih hemat |
| 10-year horizon | 0,857 | -Rp 17,1 juta | Lebih efektif dan lebih hemat |
| 20-year horizon | 1,963 | -Rp 41,0 juta | Lebih efektif dan lebih hemat |
| 0% discount rate | 6,729 | -Rp 100,8 juta | Lebih efektif dan lebih hemat |
| 5% discount rate | 2,598 | -Rp 43,8 juta | Lebih efektif dan lebih hemat |
| Real-world / genotype-3 lower efficacy (intervention SVR 90%, chronic residual 10%) | 3,348 | -Rp 53,6 juta | Lebih efektif dan lebih hemat |
| Higher branded LDV/SOF price (3x generic, ~IDR 30 million/course) | 3,682 | -Rp 40,3 juta | Lebih efektif dan lebih hemat |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| SVR12 (sustained virologic response, 12-week ledipasvir/sofosbuvir, treatment-naive genotype 1) | 99,0% | 99,0% | ION-1, Afdhal et al., NEJM 2014;370:1889-1898 (n=865 treatment-naive HCV genotype 1): SVR12 99% with 12 weeks of fixed-d |
| Annual progression chronic HCV to compensated cirrhosis (untreated) | 3,5% | 3,5% | Natural history of chronic HCV: cirrhosis develops in ~20-30% over 25-30 years of untreated infection (Westbrook & Dushe |
| Cumulative incidence of compensated cirrhosis at 10 years (untreated comparator arm) | 25,8% | 25,0% | Untreated chronic HCV cumulative cirrhosis risk ~20-30% over the disease course (Westbrook & Dusheiko, J Hepatol 2014; N |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- NICE TA363 (25 Nov 2015) recommended ledipasvir-sofosbuvir as a cost-effective option for genotype 1/4 chronic HCV; for previously untreated genotype 1 the company model gave LDV-SOF an ICER of about GBP 7,985/QALY versus peginterferon+ribavirin, well below the GBP 20,000-30,000 threshold.
- Indonesia base case compares an all-oral DAA cure against the pre-DAA / untreated natural history because that is the pragmatic counterfactual for the large undiagnosed-and-untreated reservoir; a head-to-head versus generic sofosbuvir/daclatasvir would show near-equivalence and turn on price.
- Generic DAA pricing (~USD 600 or lower) makes cure highly cost-effective in Indonesia; Trickey et al. (2020) estimated national scale-up is cost-effective at ~USD 300 per life-year saved with negotiated prices.
- Budget impact is dominated by diagnosis and linkage-to-care capacity, not drug efficacy: only a low fraction of the ~1.9 million infected are currently diagnosed and treated.
- Reviewers should verify Fornas line-listing and current e-katalog price before policy interpretation; threshold uses 1x/3x GDP proxy only and InaHTAC may apply different decision rules.